1. A liquid aqueous preparation comprising: (1) an isolated human anti-TNFα antibody or antigen binding portion thereof； (2) a surfactant； and (3) less than 50 mg / ml polyol； however, injection of the drug to a person results in pain with a visual analogue pain scale (VAS) rating of less than 1.0.2. A liquid aqueous preparation containing: (1) an isolated human anti-TNFα antibody or antigen binding portion thereof； (2) a surfactant； and (3) less than 50 mg / ml polyol； wherein the preparation does not contain buffer or salt, and the injection of the drug reduces the pain associated with the injection in humans by at least about 50% compared with the injection in the rest an identical formulation that contains salt and / or buffer. 3. A liquid aqueous preparation essentially consisting of: (1) more than 50 mg / ml of an isolated human anti-TNFα antibody or antigen binding portion thereof； (2) a surfactant； and (3) less than 50 mg / ml of the polyol, while injecting the drug into a person leads to pain with a visual analogue pain scale (VAS) rating of less than 1.0.4. The preparation according to claim 2, wherein the pain associated with the injection is evaluated using a visual analogue pain scale (VAS). The preparation according to claim 2, wherein the otherwise identical preparation contains citrate-phosphate buffer and sodium chloride. A liquid aqueous preparation containing: (1) an isolated human anti-TNFα antibody or antigen binding portion thereof； (2) a surfactant； and (3) less than 50 mg / ml of the polyol； wherein the preparation is stable up to about 30 ° C for at least 6 days. The drug according to claim 6, in which the drug is1. Жидкий водный препарат, содержащий:(1) выделенное человеческое антитело против TNFα или его антигенсвязывающую часть；(2) поверхностно-активное вещество； и(3) менее чем 50 мг/мл полиола；при этом инъекция препарата человеку приводит к боли с оценкой по визуальной аналоговой шкале боли (ВАШ) меньше 1,0.2. Жидкий водный препарат, сод
